Alana Hippensteele

Manish Agrawal, MD, discusses the expanding influence of his group-based psychedelic therapy model in oncology and beyond, highlighting its adaptation in military post-traumatic stress disorder (PTSD) research, the sustained benefits of long-term patient integration, and growing institutional interest in psychedelic-assisted therapy.

Manish Agrawal, MD, explores the evolving role of pharmacists in psychedelic-assisted therapy, highlighting ongoing efforts to develop standardized protocols and the emerging involvement of pharmacy teams in patient education and safety.

ASCO 2025: Novel Bispecific T-Cell Engager Targeting DLL3 Offers Hope for Refractory Neuroendocrine Carcinomas

Gayathri Namasivayam, PhD, discusses how large language models are being used to extract structured oncology data from unstructured electronic health records to improve clinical efficiency, support real-world evidence generation, and enhance oncology pharmacy workflows.

Precision and Protection: Inside Cone Health’s Robotic Compounding Program

Manish Agrawal, MD, discusses the implementation of psilocybin-assisted therapy in a community cancer setting, highlighting its potential to provide sustained relief from depression and anxiety and its significant efficacy advantage over selective serotonin reuptake inhibitors for patients with cancer.

Highlights From NLA 2025: Early LDL-C Reduction and Emerging Therapies

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, discusses how oncology pharmacists can lead value-based care efforts under the Enhanced Oncology Model (EOM) by improving care coordination, managing costs, aligning with performance metrics, and leveraging clinical data systems to enhance patient outcomes.

Laura R. Bobolts, PharmD, BCOP, shares actionable strategies for oncology pharmacists to navigate biosimilar and 505(b)(2) drug implementation, manage payer and formulary complexities, and optimize cost-effective care delivery across oncology service lines.

NCCN Guideline Update: Updated CML Recommendations Emphasize Distress Screening, Drug Interactions, and Cost

The Phase 1 clinical trial for ARCT-2304, a self-amplifying mRNA vaccine, seeks to address pandemic influenza risk as H5N1 cases increase.

The National Comprehensive Cancer Network (NCCN) has updated its ovarian cancer guidelines version 3.2025 to recommend niraparib as maintenance therapy for patients with BRCA wild-type or homologous recombination (HR)–deficiency who did not receive bevacizumab during primary treatment.

AI offers many benefits in health professions by efficiently handling time-consuming tasks crucial for patient care.

Psychedelic Science 2025: Lessons From MDMA Trials Could Strengthen Future Psychedelic Approvals

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses the expanding role of GLP-1 receptor agonists in holistic type 2 diabetes care, highlighting their cardio-renal-hepatic benefits, clinical access challenges, emerging investigational therapies, and practical strategies for individualized, guideline-based prescribing.

Selective reporting and underrepresentation distort biomedical evidence, affecting pharmacy practice

Two pharmacy leaders at UNC Health share how their distinct yet complementary leadership journeys and skill sets are driving innovation in clinical practice, education, and team development across the health system.

Pharmacists optimize biosimilar and 505(b)(2) use through collaboration, education, and integration.

Oncology pharmacists are increasingly shaping patient care.

Precision oncology has shifted, yet pharmacists’ roles remain underutilized.